Cardio Flashcards
‘global speckled’ pattern on ECHO
Cardiac amyloidosis
Psuedoinfarction pattern on ECG appears as
Low-voltage complexes with poor R wave progression
Pseudoinfarction pattern on ECG associated with
Cardiac amyloidosis
Normal PR interval
120 - 200 ms
Anteroseptal - ECG changes
V1 - V4
Inferior - ECG changes
II, III, aVF
Anterolateral - ECG changes
V4-V6, I, aVL
Lateral - ECG changes
I, aVL +/- V5-V6
Posterior - ECG changes
Tall R waves V1-V2
Coronary artery affected: Anteroseptal changes
Left anterior descending
Coronary artery affected: Inferior changes
Right coronary
Coronary artery affected: Anterolateral changes
Left anterior descending,
or,
Left circumflex
Coronary artery affected: Lateral changes
Left circumflex
Coronary artery affected: Posterior changes
Usually left circumflex, also right coronary
Long QT1
Adrenergic surge due to physical activity
Long QT2
Adrenergic surge due to intense emotion
Long QT3
Death during sleep
Kussmaul’s sign looks like
JVP rises during inspiration
Kussmails sign associated with
Constrictive pericarditis
Definition of pulmonary arterial hypertension
Resting mean pulmonary artery pressure is >= 25 mmHg
Wellen’s syndrome - appearance on ECG
Deeply inverted/biphasic T waves in V2 - V3
Wellen’s syndrome - suggests
Critical LAD stenosis
Aortic stenosis - Criteria for aortic valve surgery
Symptomatic
Valvular gradient > 40 mmHg and features of LV systolic dysfunction
Dabigatran MOA
Inhibits thrombin
Dabigatran reversal agent
Idarucizumab
Blood pressure target - patient with hypertension without other comorbidity
< 140/90 mmHg
Blood pressure target - patient with diabetes and end organ damage
< 130/80 mmHg
Normal QRS duration
< 120 ms
INR > 8.0 with No bleeding
Oral Vitamin K 1-5 mg
Repeat dose vitamin K if INR still too high after 24hr
Restart warfarin when INR < 5
ECG findings associated with ostium primum
RBBB + LAD, prolonged PR
ECG findings associated with ostium secundum
RBBB + RAD
Heart failure - 1st-line management for all patients
ACEi + beta-blocker
(start one, then add other)
Heart failure - 2nd-line
Aldosterone antagonist
(spironolactine/eplerenone)
Heart failure - 3rd-line options
Ivabradine
Sacubitril-valsartan
Digoxin
Hydralazine with nitrate
Cardiac resynchroniziiton therpy
Heart failure management – criteria for ivabridine
Sinus rhythm >75 bpm +
LVEF <35%
Heart failure management - criteria for sacubitril-valsartan
LVEF <35%
Heart failure management - indication for digoxin
Coexistant AF
Heart failure management - indication for hydralazine with nitrate
Afro-Caribbean patient
Heart failure management - indication for cardiac resynchronization therapy
Widened QRS complex >130ms
Infective endocarditis- empiric treatment for prosthetic valve
Vancomycin + rifampicin + low-dose gentamicin
Infective endocarditis- empiric treatment for native valve
Amoxicillin + consider low-dose gentamicin
Infective endocarditis- empiric treatment for native valve (Penicillin allergy)
Vancomycin + low-dose gentamicin
Mitral regurgitatiion with new AF - management?
Refer for mitral valve replacement
Features of cholesterol embolism
- Eosinophilia
- Purpura
- Renal failure
- Livedo reticularis
Causes of LBBB
- IHD
- HTN
- Aortic stenosis
- Cardiomyopathy
Epsilon wave looks like
Small positive deflection at end of QRS complex
Infective endocarditis - treatment for prosthetic valve, caused by staphylococci
Flucloxacillin + rifampicin + low-dose gentamicin
Prolonged QTc in men
> 440ms
Infective endocarditis - treatment for native valve, caused by staphylococci (PEN ALLERGIC)
Vancomycin + rifampicin
Acceptable increase in creatinine when starting AECi
Up to 30% increase
Infective endocarditis - treatment for prosthetic valve, caused by MRSA
Vancomycin + rifampicin + low-dose gentamicin
Secundum atrial septal defects occur where
Middle of atrial septum
Infective endocarditis - treatment if caused by fully-sensitive streptococci eg viridans (PEN ALLERGIC)
Vancomycin + low-dose gentamicin
Infective endocarditis - treatment if caused by less-sensitive streptococci (PEN ALLERGIC)
Vancomycin + low-dose gentamicin
Infective endocarditis - treatment if caused by less-sensitive streptococci
Benzylpenicillin + low-dose gentamicin
Causes of LBBB
- IHD
- HTN
- Aortic stenosis
- Cardiomyopathy
Culture-negative causes of infective endocarditis
Coxiella burnetii
Bartonella
Brucella
HACEK
Prior antibiotics
Which pre-excitation disorder shows ECG with a short PR interval, and normal QRS complex
Lown-Ganong-Levine syndrome
ECG findings in Wolff-Parkinson-White syndrome
Short PR interval, wide QRS complex with slurred upstroke (delta wave)
PMH contraindications to adenosine use in SVT
Asthma
Taking dipyridamole
ECG findings in dextrocardia
Inverted P wave in lead I
RAD
Loss of R wave progression
Patient with WPW in AF - which medication for cardioversion
Flecainide
Unifying diagnosis: Constrictive pericarditis + nephrotic syndrome + mononeuritis multiplex
Amyloidosis
Digoxin contraindication
Cardiac amyloidosis (digoxin binds to amyloid > toxicity)
1st line management of acute idiopathic/viral pericarditis
NSAID + colchicine
HACEK agents
Haemophilus
Actinobacillus
Cardiobacterium
Eikenella
Kingella
Culture-negative causes of infective endocarditis
Coxiella burnetii
Bartonella
Brucella
HACEK
Prior antibiotics
ECG findings in dextrocardia
Small complexes in chest leads vs the limb leads
Inverted complexes in I and aVL
ECG findings in Second-degree AV block type 1 (Mobitz I, Wenckebach)
Progressive prolongation of PR interval until a dropped beat occurs
ECG findings in Second-degree AV block type 2 (Mobitz II)
P waves are often not followed by a QRS complex.
Where a QRS complex does follow, the PR interval is NORMAL
CHA2DS2-VASc
CCF - 1
HTN - 1
Age:
=>75 - 2
65-74 - 1
DM - 1
Stroke/TIA - 2
IHD/PAD - 1
Female - 1
Hypertension - 4th line medical management
(already taking A + C + D)
- K < 4.5 mmol/l
Add low-dose spironolactone
Hypertension - 4th line medical management
(already taking A + C + D)
- K > 4.5 mmol/l
Add alpha-blocker (doxazosin) or beta-blocker (nebivolol, carvedilol)
Beta-blockers in systemic sclerosis
May worsen Raynauds
Hypertension - 3rd line management, already taking ACEi + CCB
Thiazide-like diuretic (Indapamide)
Hypertension - 1st line management <55 years old and not AFC
ACEi/ARB
Hypertension - 1st line management any age, with T2DM, not AFC
ACEi/ARB
Hypertension - 1st line management >55 years old not T2DM
Calcium channel blocker (amlodipine)
Hypertension - 1st line management any age, AFC, not T2DM
Calcium channel blocker (amlodipine)
Hypertension - 2nd line management - already taking ACEi/ARB
Add:
CCB (amlodipine)
or
TLD (indapamide)
Hypertension - 2nd line management - already taking CCB
Add:
ACEi or ARB (ARB if AFC)
or
TLD (indapamide)
Hypertension - 3rd line management, already taking ACEi + TLD
Add CCB
Patient with AF, already on dual anti-platelet
Still needs formal anticoagulation (Warfarin/DOAC)
Which anti-coagulant for AF, in patient with CKD?
Rivaroxaban
(Reduced dose if GFR 15-50)
Dabigatran in renal impairment
Not safe, high risk of bleeding
Cardiac monitor shows ‘short runs of polymorphic VT’
Torsades de pointes
Management of Torsades de pointes
IV Magnesium sulphate
Causes of long QT (therefore increase risk of Torsades de pointes)
Amiodarone, sotalol
Erythromycin/clarithromycin
Low Ca, K, Mg
TCA/antipsychotics
Chloroquine
Fluconazole
Management of monomorphic VT - no adverse signs
Amiodarone/
Lidocaine/
Procainamide
Management of monomorphic VT - with adverse signs
DC cardioversion
ECG findings in Brugada syndrome
Coved ST elevation in >1 of V1-V3 followed by negative T wave
Diagnostic tool for Brugada
Flecainide challenge
Management of Brugada syndrome
ICD
Long-term management of WPW
Radiofrequency ablation
Medical management of SVT in WPW
Sotalol, adenosine, flecainide, amiodarone
CI to use of sotalol/adenosine in for SVT in WPW
Possible underlying AF
Which type of atrial septal defect is most common
Ostium secundum defect
ST elevation without reciprocal depression, shortly after myocardial infarction, suggests
Left ventricle aneurysm
Feature that suggests vascular claudication (over neurogenic claudication)
No relief from leaning forward/sitting down.
Only relieved with rest
ABPI > 1.2
Calcified stiff arteries
May be PAD or normal in old age
ABPI 1.0 - 1.2
Normal
ABPI 0.9 - 1.0
Acceptable
ABPI < 0.9
Likely PAD
ABPI < 0.5
Severe PAD - urgent referral
ABPI required for compression bandaging
> = 0.8
ECG features of trifascicular block
RBB + LAD/RAD + prolonged PR
Management of sick sinus syndrome with bradarrhythmia
Pacemaker (AAIR)
Inherited long QT and sensorineural hearing loss seen in
Jervell & Lange-Nielson syndrome
Congenital syndrome with long QT (no hearing loss)
Romano-Ward syndrome
CHA2DS2-VASc
CCF - 1
HTN - 1
Age:
=>75 - 2
65-74 - 1
DM - 1
Stroke/TIA - 2
IHD/PAD - 1
Female - 1
CHADS-VaSc 1 (male)
Consider anticoagulation with DOAC (Rivaroxaban)
CHADS-VaSc 1 (female)
No anticoagulation
(Need ECHO to exclude valvular heart disease)
CHADS-VaSc 2
Offer anticoagulation with DOAC
Normal PR interval
120 - 200 ms
Anteroseptal - ECG changes
V1 - V4
Inferior - ECG changes
II, III, aVF
Anterolateral - ECG
V4-V6, I, aVL
Lateral - ECG changes
I, aVL +/- V5-V6
Posterior - ECG changes
Tall R waves V1-V2
Coronary artery affected: Anteroseptal changes
Left anterior descending
Coronary artery affected: Inferior changes
Right coronary
Coronary artery affected: Anterolateral changes
Left anterior descending,
or,
Left circumflex
Coronary artery affected: Lateral changes
Left circumflex
Coronary artery affected: Posterior changes
Usually left circumflex, also right coronary
Definition of pulmonary arterial hypertension
Resting mean pulmonary artery pressure is >= 25 mmHg
Normal QRS duration
< 120 ms
INR > 8.0 with No bleeding
Oral Vitamin K 1-5 mg
Repeat dose vitamin K if INR still too high after 24hr
Restart warfarin when INR < 5
Heart failure - 1st-line management for all patients
ACEi + beta-blocker
(start one, then add other)
Heart failure - 2nd-line
Aldosterone antagonist
(spironolactone/eplerenone)
Heart failure - 3rd-line options
Ivabradine
Sacubitril-valsartan
Digoxin
Hydralazine with nitrate
Cardiac resynchroniziiton therpy
Heart failure management – criteria for ivabridine
Sinus rhythm >75 bpm +
LVEF <35%
Criteria for using sacubitril-valsartan (Entresto) for heart failure
LVEF <35%
Heart failure management - indication for digoxin
Coexistant AF
Heart failure management - indication for hydralazine with nitrate
Afro-Caribbean patient
Heart failure management - indication for cardiac resynchronization therapy
Widened QRS complex >130ms
Widened QRS complex >130ms
- IHD
- HTN
- Aortic stenosis
- Cardiomyopathy
Prolonged QTc in men
> 440ms
Causes of LBBB
- IHD
- HTN
- Aortic stenosis
- Cardiomyopathy
Hypertension - 4th line medical management
(already taking A + C + D)
- K < 4.5 mmol/l
Add low-dose spironolactone
Hypertension - 4th line medical management
(already taking A + C + D)
- K > 4.5 mmol/l
Add alpha-blocker (doxazosin) or beta-blocker (nebivolol, carvedilol)
Angina - all patients should be on
(in absence of contraindications)
Aspirin
Statin
Sublingual GTN prn
Angina - 1st line treatment
Beta-blocker + Calcium channel blocker
Medications which may exacerbate heart failure
Thiazolidinediones (pioglitazone)
Verapamil
NSAIDs
Glucocorticoids
Class I antiarrhythmics (flecainide)
Severe hypertension requiring same-day specialist assessment/admission.
BP >=180/120 and any of:
- Retinal haemorrhage /papilloedema
- New confusion
- Chest pain
- Signs of heart failure
- AKI
Most appropriate first-line anti-anginal for stable angina in a patient with heart failure.
Bisoprolol (beta-blocker)
If calcium channel blocker is used as monotherapy in stable angina - which one should be used?
Rate-limiting CCB (verapamil, diltiazem)
If calcium channel blocker is used in combo with beta-blocker in stable angina - which one should be used?
Long-acting dihydropyridine CCB (modified-release nifedipine).
Verapamil should never be prescribed with
Beta-blockers (risk of complete heart block)
Stage 1 HTN - clinic reading
> =140/90 mmHg
Stage 1 hypertension - criteria (ABPM/HBPM)
Average >= 135/85 mmHg
Stage 2 hypertension - criteria (clinic reading)
> =160/100 mmHg
Stage 2 hypertension - criteria (ABPM/HBPM)
Average >= 150/95 mmHg
Severe hypertension - criteria
Systolic BP >= 180 mmHg
or
Diastolic BP >= 120 mmHg
Clopidogrel effectiveness may be reduced by concurrent use of:
Omeprazole/esomeprazole
(lansoprazole ok)
At what eGFR should thiazide diuretics be avoided in CKD?
eGFR <30 ml/min (CKD stage 4)
Hypertension - 1st line management <55 years old and not AFC
ACEi/ARB
Hypertension - 1st line management any age, with T2DM, not AFC
ACEi/ARB
Hypertension - 1st line management >55 years old not T2DM
Calcium channel blocker (amlodipine)
Hypertension - 1st line management any age, AFC, not T2DM
Calcium channel blocker (amlodipine)
Hypertension - 2nd line management - already taking ACEi/ARB
Add:
CCB (amlodipine)
or
TLD (indapamide)
Hypertension - 2nd line management - already taking CCB
Add:
ACEi or ARB (ARB if AFC)
or
TLD (indapamide)
Hypertension - 3rd line management, already taking ACEi + TLD
Add CCB
Hypertension - 3rd line management, already taking ACEi + CCB
Thiazide-like diuretic (Indapamide)
Myocardial infarction secondary prevention - all patients should be offered
- Dual antiplatelet therapy
- ACEi
- Beta-blocker
- Statin
Myocardial infarction secondary prevention - with signs of heart failure + reduced LVEF
Aldosterone antagonist (eplerenone)
Timing of initiation aldosterone antagonist post-MI
Within 3-14 days of MI
After ACEi initiated
Dual antiplatelet therapy following medically-managed ACS
Aspirin life-long
+
Ticagrelor for 12 months
Dual antiplatelet therapy following PCI
Aspirin life-long
+
Ticagrelor or prasugrel for 12 months
Anti-thrombotic therapy for bio-prosthetic heart valve
Aspirin
Anti-thrombotic therapy for mechanical prosthetic heart valve
Warfarin + aspirin
DVLA advice post ACS (successful angioplasty)
1 week off driving
DVLA advice post ACS
(not successfully treated by angioplasty)
4 weeks of driving
DVLA advice post elective angioplasty
1 week off driving
DVLA advice post CABG
4 weeks off driving
DVLA advice post pacemaker insertion
1 week off driving
1st-line agents for long-term rate-control in AF
standard beta-blocker
or
rate-limiting calcium channel blocker (diltiazem)
Indication to use digoxin as rate-limiting agent in AF
Sedentary
Beta-blocker/CCB not appropriate
Co-existent heart failure
Caution/CI for ACEi
Pregnancy/breastfeeding
Renovascular disease
Aortic stenosis
Hereditory angioedema
Potassium >= 5.0
Amiodarone - baseline tests prior to starting
TFT, LFT, U&E, CXR
Amiodarone - monitoring
TFT, LFT 6-monthly
Drugs which cause QT prolongation
Amiodarone
Sotalol
TCAs
SSRIs (especially citalopram)
Chloroquine
Erythromycin
Haloperidol
Ondansetron
Target clinic BP if patient <80y
140/90 mmHg
Target clinic BP if patient >=80y
150/90 mmHg
Target ABPM/HBPM if patient <80y
135/85 mmHg
Target ABPM/HBPM if patient >=80y
145/85 mmHg
Target clinic BP: Type 1 diabetes without albuminuria/metabolic syndrome
135/85 mmHg
Target clinic BP: Type 1 diabetes with albuminuria or metabolic syndrome
130/80 mmHg
Target BP in CKD with Diabetes
<130/80 mmHg
Target BP in CKD (not diabetic, ACR <70)
<140/90 mmHg
Target BP in CKD (not diabetic, but ACR >70)
<130/80 mmHg
Target clinic BP in T2DM (no CKD)
Same as gen pop:
Under 80y <140/90
Over 80y <150/90
Target INR for aortic mechanical valve
3.0
Target INR for mitral mechanical valve
3.5
Blood test monitoring for statins
LFTs at baseline, 3 months + 12 months
Investigation for suspected IHD (non-acute) - 1st line
CT coronary angiography
Investigation for suspected IHD (non-acute) - 2nd line
Non-invasive functional imaging
(MR perfusion scan, stress echo)
Investigation for suspected IHD (non-acute) - 3rd line
Invasive coronary angiography
DVLA post ICD insertion for HOCM (no history of arrhythmia)
4 weeks off driving
Amlodipine maximum dose
10mg per day
A side effect of which cardiac medication is ulceration?
Nicorandil (vasodilator used in angina)
Statins in pregnancy
Contraindicated in pregnancy and pre-conception (congenital anomaly)
If suspect chronic heart failure
NT-pro-BNP
ECG
Tests for other causes/aggravators
Suspected CHF and NT-pro-BNP >2000
2 week referral for ECHO + cardiologist
Suspected CHF and NT-pro-BNP 400-2000
6-week referral for ECHO + cardiologist
Offer statin for primary prevention to:
=10% + lifestyle ineffective
=10% + T2DM
T1DM + age 40y+/diagnosed >10y/nephropathy/CVD RF
CKD
Familial hypercholesterolaemia
Offer statin (without risk assessment) to T1DM if: *
> 40y
Diagnosed >10y ago
Nephropathy
CVD risk factors
Offer statin (without risk assessment) to
Certain T1DM pt*
CKD
Familial Hypercholesterolaemia
Consider offering statin (without risk assessment) to
> =85y
All with T1DM
All T1DM
<85y QRISK >10% + no T2DM
Lifestyle modification first (if appropriate)
Offer statin
<85y QRISK >10% + T2DM
Offer statin
Statin for primary prevention - followup
Repeat TC, HDL, non-HDL in 3m
Looking for 40% reduction in non-HDL
Statin for primary prevention
atorvastatin 20mg
Statin for secondary prevention
atorvastatin 80mg
Who should receive a statin
- Known CVD (stroke/TIA, IHD, PAD)
- 10 year CV risk >= 10%
- T1DM diagnosed >10y, or, aged >40, or nephropathy
NSTEMI immediate management
- aspirin 300mg
- nitrates/morphine PRN
- oxygen only if hypoxic
- Fondaparinux (UFH if PCI within 24h/poor renal function)
- Ticagrelor for 12 months
-Tirofiban (gpIIb/IIIa receptor antagonist)
Coronary angiography within 96hr
Management of Torsades de pointes
IV magnesium sulphate
Acute pericarditis - management
Treat underlying cause
NSAID + colchicine
Antiplatelet therapy - after ACS (medically treated)
Aspirin lifelong +
Ticagrelor 12 months
Antiplatelet therapy - after ACS (PCI)
Aspirin lifelong +
Prasurgrel/ticagrelor 12 months
Antiplatelet therapy - after TIA
Clopidogrel lifelong
Antiplatelet therapy - after ischaemic stroke
Clopidogrel lifelong
Antiplatelet therapy - peripheral arterial disease
Clopidogrel lifelong